Laura Goff
Faculty Member
Last active: 3/11/2014

  1. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E (2014) Cancer Med 3(3): 572-9
    › Primary publication · 24574334 (PubMed) · PMC4101748 (PubMed Central)
  2. Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Venepalli NK, Goff L (2013) Int J Hepatol : 341636
    › Primary publication · 23606971 (PubMed) · PMC3626399 (PubMed Central)
  3. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. Infante JR, Bendell JC, Goff LW, Jones SF, Chan E, Sudo T, Burris HA, Berlin JD (2013) Eur J Cancer 49(6): 1169-75
    › Primary publication · 23294608 (PubMed)
  4. Current therapy and future directions in biliary tract malignancies. Ciombor KK, Goff LW (2013) Curr Treat Options Oncol 14(3): 337-49
    › Primary publication · 23686724 (PubMed) · PMC3769474 (PubMed Central)
  5. Advances in the management of biliary tract cancers. Ciombor KK, Goff LW (2013) Clin Adv Hematol Oncol 11(1): 28-34
    › Primary publication · 23416860 (PubMed) · PMC3713630 (PubMed Central)
  6. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML (2012) Invest New Drugs 30(1): 290-8
    › Primary publication · 20857171 (PubMed)
  7. Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review. Chi M, Mikhitarian K, Shi C, Goff LW (2012) Gastrointest Cancer Res 5(6): 199-202
    › Primary publication · 23293701 (PubMed) · PMC3533848 (PubMed Central)
  8. Advanced biliary tract cancers. Goff LW, Berlin JD (2012) Am Soc Clin Oncol Educ Book : 281-2
    › Primary publication · 24451749 (PubMed)
  9. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM (2011) J Clin Oncol 29(17): 2350-6
    › Primary publication · 21519015 (PubMed) · PMC3107750 (PubMed Central)
  10. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA (2011) J Clin Oncol 29(17): 2357-63
    › Primary publication · 21519026 (PubMed) · PMC3107751 (PubMed Central)